Pharmaceutical

Novo Nordisk and Broad Institute to explore drug targets for diabetes, CMDs 

Novo Nordisk has entered a collaboration with The Broad Institute to detect drug targets for Type 2 diabetes and cardiometabolic diseases.

Sep 7, 2023 - 20:00
Novo Nordisk and Broad Institute to explore drug targets for diabetes, CMDs 
Novo Nordisk has entered a collaboration with The Broad Institute to detect drug targets for Type 2 diabetes and cardiometabolic diseases.
Read the original article

Tags:

Previous Article

IMIDomics to license TNAX’s drug candidate for IMIDs

Next Article

Apollo Therapeutics secures $226.5m to advance pipeline programmes

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Tacalyx extends seed funding round to raise over €14m

Tacalyx extends seed funding round to raise over €14m

Jun 12, 2024

LAPIX receives US patent for LPX-TI641 to treat autoimmune diseases

LAPIX receives US patent for LPX-TI641 to treat autoimm...

May 18, 2023

Climate change may aggravate multiple sclerosis

Climate change may aggravate multiple sclerosis

Jun 6, 2024